Bigender
Two gender identities at the same time or alternately.
A person who is bigender experiences two distinct gender identities—usually male and female—either simultaneously or alternately. Bigender individuals may also combine two non-binary identities.
Bigender is one of the earlier non-binary identity labels and appeared as early as the 1980s in transsexual and transgender literature. The term is not medically recognized but is used for self-identification and sometimes on identity documents in countries with an X-gender option.
Critical Analysis
Bigender illustrates how gender identities are being classified in increasingly nuanced ways. The question is whether this categorization describes or constructs reality—and whether encouraging young people to develop two separate gender personas is psychologically healthy.
Related identities:
Related topics:
Origin and spread
The Bigender identity emerged in online subcultures on Tumblr, Reddit, and TikTok in the 2010s. Its growth did not stem from clinical research or anthropological description, but rather from self-identification and peer validation. What begins as a personal experience rapidly becomes an established category within those circles, complete with its own flag, pronouns, and strict definitions.
The spread occurs almost entirely through social media and youth culture. That is no minor detail. ROGD (Rapid Onset Gender Dysphoria) research suggests that social clustering—groups of friends in which multiple young people simultaneously develop a new identity—is a significant explanatory factor. The gender-affirming sector ignores this signal or dismisses it as transphobic, while parents and clinicians do observe it in practice.
Test against clinical evidence
An identity label only becomes medically relevant when it leads to interventions: social transition, puberty blockers, cross-sex hormones, surgeries. It is precisely at this point that the house of cards that is the evidence base collapses. The Cass Review (2024) describes the evidence base for puberty blockers and hormones in minors as weak. NICE (2020) classified all relevant studies as having very low certainty.
Sweden (SBU, 2022) and Finland (COHERE, 2020) reverted their protocols to a “psychotherapy-first” approach. Norway (UKOM, 2023) described the care as experimental. NHS England ceased the routine prescribing of puberty blockers. The WPATH Files (2024) revealed that even WPATH clinicians were debating among themselves about informed consent and irreversible side effects.
Why this resistance is justified
The proliferation of identity labels such as Bigender is not an innocent linguistic innovation. It serves as a gateway to medical treatment for young people struggling with ordinary adolescent uncertainty. Detransitioners—people who reverse their transition—describe how, in their search for themselves, they were affirmed at every step toward medicalization, and rarely encountered anyone who put the brakes on.
Resistance to this dynamic often comes from mothers, lesbian women, pediatricians, and psychiatrists who see what is happening and break their silence despite the career risks. Their voices should no longer be dismissed as hate—they describe a reality that the gender-affirmative model refuses to see.
International Reconsideration
In recent years, several national health authorities have distanced themselves from the gender-affirming model for minors. The common denominator: the evidence for lasting benefits is lacking, while the risks are real.
Cass Review (2024). Review commissioned by NHS England, conducted by Hilary Cass. Conclusion: the evidence base for puberty blockers and cross-sex hormones in minors is weak. NHS England ceased routine prescribing of puberty blockers outside of clinical trials.
SBU — Sweden (2022). The Swedish Agency for Health Technology Assessment (SBU) and Karolinska University Hospital discontinued the use of puberty blockers and hormones for minors outside of clinical trials. Reason: lack of evidence for effectiveness and safety.
NICE — United Kingdom (2020). Two NICE evidence reviews (puberty blockers and cross-sex hormones) classified the evidence base as very low certainty. None of the studies identified met modern methodological standards.
COHERE — Finland (2020). The Finnish Council for Choices in Health Care revised its protocol: psychotherapy as the first line of care, medical transition for minors only in exceptional cases and within a research setting.
UKOM — Norway (2023). The Norwegian UKOM classified transgender care for minors as experimental; existing protocols do not meet the requirements for evidence-based care.
WPATH Files (2024). Internal discussions among WPATH clinicians acknowledge that informed consent for minors is problematic and that serious side effects (bone density, fertility, cognitive development) are not adequately explained.